Pallido-nigral degeneration--a case of Parkinson's syndrome resistant to L-dopa
Matsuoka, Y.; Muroga, T.; Wakayama, Y.; Sugimura, K.; Matsui, T.
Rinsho Shinkeigaku 17(1): 46-51
1977
ISSN/ISBN: 0009-918X PMID: 557400 Document Number: 119871
Document emailed within 1 workday
Related Documents
McGeer, P.L.; Fibiger, H.C.; Maler, L.; Hattori, T.; McGeer, E.G. 1974: Evidence for descending pallido-nigral GABA-containing neurons Advances in Neurology 5: 153-160Bergonzi, P.; Chiurulla, C.; Gambi, D.; Mennuni, G.; Pinto, F. 1975: L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment Acta Neurologica Belgica 75(1): 5-10
Christiani, K.; Möller, W.D. 1973: Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor Münchener Medizinische Wochenschrift 115(16): 711-713
Glabb, J.; Hübner, W.; Glabb, S. 1973: Treatment of Parkinson's syndrome using L-dopa. 2 Zeitschrift für Arztliche Fortbildung 67(15): 745-753
Pimenta, A.d.M.; Friguglietti, D.J. 1971: Treatment of Parkinson's syndrome with L-dopa. in operated and nonoperated cases Revista Brasileira de Medicina 28(9): 481-496
Fischer, P.A.; Schneider, E.; Jacobi, P.; Maxion, H. 1973: Combination therapy of Parkinson's syndrome using L-dopa and a decarboxylase inhibitor Die Medizinische Welt 24(45): 1742-1746
Lombardo, L. 1973: Efficacy and side effects of L-dopa in patients with Parkinson's syndrome Archivos de Investigacion Medica 4(3): 215-224
Guillard, A. 1972: Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor Bruxelles Medical 52(10): 673-680
Routh, J.I.; Bannow, R.E.; Fincham, R.W.; Stoll, J.L. 1971: Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy Clinical Chemistry 17(9): 867-871
Gauthier, G.; de Ajuriaguerra, J.; Geissbuhler, F.; Simona, B.; Constantinidis, J.; Yanniotis, G.; Krassoievitch, M.; Eisenring, J.J.; Tissot, R. 1971: Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa? La Presse Medicale 79(3): 91-92
Muenter, M.D.; Tyce, G.M. 1971: L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects Mayo Clinic Proceedings 46(4): 231-239
Hattori, N.; Mizuno, Y. 1999: Parkin gene and its function; a key to understand nigral degeneration Rinsho Shinkeigaku 39(12): 1259-1261
Indo, T.; Takahashi, A. 1987: Should L-dopa therapy for Parkinson's disease be started early or late? Clinical course of the major tetrad in 122 Parkinsonian patients treated with L-dopa over 14 years Rinsho Shinkeigaku 27(11): 1419-1422
Halperin, J.J.; Williams, R.S.; Kolodny, E.H. 1982: Microcephaly vera, progressive motor neuron disease, and nigral degeneration Neurology 32(3): 317-320
Friedman, A.; Galazka-Friedman, J. 2001: The current state of free radicals in Parkinson's disease. Nigral iron as a trigger of oxidative stress Advances in Neurology 86: 137-142
Panagariya, A.; Sharma, B.; Dev, A. 2007: Pallido-pyramidal syndrome: a rare entity Indian Journal of Medical Sciences 61(3): 156-157
Dalle Ore, G.; Bricolo, A.; Robotti, E.; Bazzan, A.; Mazza, C. 1970: The treatment of Parkinson's disease with L-dopa Il Policlinico. Sezione Pratica 77(16): 509-524
Lees, A.J. 1986: L-dopa treatment and Parkinson's disease Quarterly Journal of Medicine 59(230): 535-547
Völler, G. 1970: L-dopa in the treatment of Parkinson's disease Die Medizinische Welt 27: 1267-1268
Henry, P.; Lacut, J.Y.; Pouget-Abadie, J.; Bergouignan, M.; Leng-Lĕvy, J. 1971: One year of experience with L-Dopa in Parkinson's disease Bordeaux Medical 4(5): 1581-1591